873009-27-9

Basic information

• Product Name: CarbaMic acid, N-[(1R)-3,3-dibroMo-1-Methyl-2-propen-1-yl]-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-[(1R)-3,3-dibroMo-1-Methyl-2-propen-1-yl]-, 1,1-diMethylethyl ester;(R)-tert-Butyl (4,4-dibromobut-3-en-2-yl)carbamate
• CAS NO: 873009-27-9
• Molecular Formula: C9H15Br2NO2
• Molecular Weight: 329.0289
• Mol File: 873009-27-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CarbaMic acid, N-[(1R)-3,3-dibroMo-1-Methyl-2-propen-1-yl]-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-[(1R)-3,3-dibroMo-1-Methyl-2-propen-1-yl]-, 1,1-diMethylethyl ester(873009-27-9)
• EPA Substance Registry System: CarbaMic acid, N-[(1R)-3,3-dibroMo-1-Methyl-2-propen-1-yl]-, 1,1-diMethylethyl ester(873009-27-9)

Safety Data

• Hazardous Substances Data: 873009-27-9(Hazardous Substances Data)

Upstream product

• 558-13-4 carbon tetrabromide 
• 79069-50-4 Boc-Ala-H 
• 82353-56-8 (2R)-2-N-t-butoxycarbonyl-aminopropanal 

Relevant articles and documents

Heterocyclic Compounds Useful as RAF Kinase Inhibitors

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

COMPOUNDS USEFUL AS RAF KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

A new stereoselective synthesis of chiral γ-functionalized (E)-allylic amines

Chiral t-Boc protected propargylic amines have been obtained starting from aminoaldehydes derived from natural aminoacids. Stannylcupration of these substrates affords an easy regio- and stereocontrolled route to the corresponding γ-stannylated (E)-allylamines which are useful intermediates for the synthesis of the corresponding γ-functionalized allylic systems.

Stereospecific synthesis of chiral alkinylogous amino acids

tert-Butoxycarbonyl (Boc)-protected a-amino aldehydes, conventionally prepared from the corresponding (S)-α-amino acids, are converted via the Corey-Fuchs reaction into the N-protected alkinylogous amino acids, which on deprotection yield the correspondin